Showing results (131-140 of 163) with videos related to

Sort By:
Pageof 17
Blood|November 26, 2015
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patientsMichael W Deininger, J Graeme Hodgson, Neil P Shah, et al.
Journal of Medicinal Chemistry|February 19, 2019
Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic CancerAndrew E Shouksmith, Fenil Shah, Michelle L Grimard, et al.
Blood|September 5, 2021
Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AMLFei Yang, Nicola Long, Tauangtham Anekpuritanang, et al.
Blood|January 10, 2015
shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistanceJamshid S Khorashad, Anna M Eiring, Clinton C Mason, et al.
Blood|December 11, 2012
BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationshipsJamshid S Khorashad, Todd W Kelley, Philippe Szankasi, et al.
Cancer Research|October 23, 2012
Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screeningJeffrey W Tyner, Wayne F Yang, Armand Bankhead, et al.
Leukemia|June 6, 2017
HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemiaS Tharkar-Promod, D P Johnson, S E Bennett, et al.
Cancer Cell|July 18, 2006
Activating alleles of JAK3 in acute megakaryoblastic leukemiaDenise K Walters, Thomas Mercher, Ting-Lei Gu, et al.
Nature Medicine|December 7, 2021
Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trialJason Gotlib, Andreas Reiter, Deepti H Radia, et al.
The Lancet. Oncology|April 17, 2016
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trialJeffrey H Lipton, Charles Chuah, Agnès Guerci-Bresler, et al.
Pageof 17